Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia

Table 3

Switching to or from ziprasidone-reasons for switch of antipsychotics.

Reason for switch	ZIP+ switch to ziprasidone	ZIP− switch from ziprasidone	Difference 𝜒^2 test
𝑁	24	27
Positive symptoms^a	6 (25.0%)	13 (48.1%)	𝑃=0.088
Depression^a	6 (25.0%)	2 (7.4%)	𝑃=0.085
Negative symptoms^a	5 (20.8%)	7 (25.9%)	n.s.
Sedation^b	1 (4.2%)	3 (11.1%)	n.s.
Weight gain^b	8 (33.3%)	1 (3.7%)	𝑃=0.006
Agitation^b	—	1 (3.7%)	n.s.
EPS^b	5 (20.8%)	1 (3.7%)	𝑃=0.058
Other side effects^b	2 (8.3%)	1 (3.7%)	n.s.
Patient’s choice^c	4 (16.7%)	10 (37.0%)	𝑃=0.10

More than one reason possible (multiple entries); ^alack of effectiveness; ^bside effects; ^cpatients' choice; EPS, extrapyramidal symptoms.